PubMedCrossRef 23. Ramsay RG: c-Myb a stem-progenitor cell regulator in multiple tissue compartments. Growth Factors 2005, 23: 253–261.PubMedCrossRef 24. Fang F, Rycyzyn MA, Clevenger CV: Role of c-Myb during prolactin-induced signal transducer and activator of transcription 5a signaling in breast cancer cells. learn more Endocrinology 2009, 150: 1597–1606.PubMedCrossRef 25. Ramsay RG, Friend A, Vizantios Y, Freeman R, Sicurella C, Hammett F, Armes J, Venter D: Cyclooxygenase-2, a colorectal cancer nonsteroidal anti-inflammatory

drug target, is regulated by c-MYB. Cancer Res 2000, 60: 1805–1809.PubMed 26. Biroccio A, Benassi B, D’Agnano I, D’Angelo C, Buglioni S, Mottolese M, Ricciotti A, Citro G, Cosimelli M, Ramsay RG, et al.: c-Myb and Bcl-x overexpression predicts poor prognosis in colorectal cancer: clinical and experimental findings. Am J Pathol 2001, 158: 1289–1299.PubMedCrossRef 27. Greco C, Alvino S, Buglioni S, Assisi D, Lapenta R, Grassi A, Stigliano V, Mottolese M, Casale V: Activation

of c-MYC and c-MYB proto-oncogenes is associated with decreased PLX 4720 apoptosis in tumor colon progression. Anticancer Res 2001, 21: 3185–3192.PubMed 28. Yang H, Huang ZZ, Wang J, Lu SC: The role of c-Myb and Sp1 in the up-regulation of methionine adenosyltransferase 2A gene expression in human hepatocellular carcinoma. FASEB J 2001, 15: 1507–1516.PubMedCrossRef 29. Chakraborty G, Jain S, Behera R, Ahmed M, Sharma P, Kumar V, Kundu GC: The multifaceted roles of osteopontin in cell signaling, tumor progression and angiogenesis. Curr Mol Med 2006, 6: 819–830.PubMedCrossRef 30. Ali SA, Zaidi SK, Dacwag CS, Salma N, Young DW, Shakoori AR, Montecino MA, Lian JB, van Wijnen AJ, Imbalzano AN, et al.: Phenotypic transcription factors epigenetically mediate cell growth control. Proc Natl Acad Sci USA 2008, 105: 6632–6637.PubMedCrossRef 31. Abaza MS, Al-Attiyah

RJ, Al-Saffar AM, Al-Sawan SM, Moussa NM: Antisense oligodeoxynucleotide directed against c-myb has anticancer activity and potentiates the antiproliferative effect of conventional anticancer drugs acting by different mechanisms in human colorectal cancer cells. Tumour Biol 2003, 24: 241–257.PubMedCrossRef 32. Ramsay RG, Barton AL, Gonda TJ: Targeting c-Myb expression in human Lonafarnib molecular weight disease. Expert Opin Ther selleck kinase inhibitor Targets 2003, 7: 235–248.PubMedCrossRef 33. Funato T, Satou J, Kozawa K, Fujimaki S, Miura T, Kaku M: Use of c-myb antisense oligonucleotides to increase the sensitivity of human colon cancer cells to cisplatin. Oncol Rep 2001, 8: 807–810.PubMed Competing interests The authors declare that they have no competing interests. Authors’ contributions CRX and SLY designed the study. CRX, YHX and TCX performed experiments. CRX drafted the manuscript. All authors read and approved the final manuscript.”
“Introduction The prostate gland is the site of two most pathological processes among elderly men, benign prostatic hyperplasia (BPH) and prostate cancer (PC) [1].